Pilot Efficacy Study of T2000 in Myoclonus Dystonia

Sponsor

Taro Pharmaceuticals USA (Industry)

Overall Status

Terminated

CT.gov ID

NCT00506012

Collaborator

(none)

Enrollment

Location

Arm

Duration (Months)

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This pilot study will evaluate the safety and efficacy of once daily T2000 when used to treat patients with Myoclonus Dystonia over a 12 week period.

Condition or Disease	Intervention/Treatment	Phase
Myoclonus	Drug: T2000	Phase 2

Detailed Description

Myoclonus Dystonia (M-D) is a rare, inherited movement disorder in which patients experience myoclonus - sudden, brief, jerky involuntary motions, often in association with dystonia - involuntary sustained contractions causing twisting or abnormal posture. While most M-D patients respond significantly to alcohol, there are no approved medications for M-D. A variety of medications are currently used to treat M-D, but these treatments work in a small proportion of patients and provide only partial improvement in symptoms; their use is also limited by side-effects in many patients.

T2000 is a medication currently under development for the treatment of movement disorders, including essential tremor (ET). Although T2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. In previous studies, T2000 appeared to be effective in controlling symptoms of ET and some patients with severe ET had major improvements in tremor. As would be expected for medications in this class, T2000 can cause sedation at high blood levels, such as may be seen when large doses are given to older individuals. In younger patients, T2000 caused only minimal side effects even when administered at high doses and for periods of several weeks to several months.

The current study will evaluate the safety and efficacy of T2000 in patients with M-D. Patients will receive doses of T2000 beginning at 200 mg a day and increasing every other week by an additional 200 mg a day up to a maximal dose of 1000 mg a day. The total duration of treatment will be 12 weeks. Patient's symptoms of myoclonus and dystonia, as well as overall neurological examination, will be monitored throughout the study. The response to T2000 will be determined by comparing the severity of myoclonus and dystonia while patients are receiving T2000 compared to the symptoms observed without active medication.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

5 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Myoclonus Dystonia: An Open Label Sequential Dose Escalation Study

Study Start Date :

Aug 1, 2007

Actual Primary Completion Date :

Aug 1, 2011

Actual Study Completion Date :

Oct 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 T2000	Drug: T2000 T2000 at doses of 200 mg a day to 1000 mg a day

Arm

Intervention/Treatment

Experimental: 1

T2000

Drug: T2000

T2000 at doses of 200 mg a day to 1000 mg a day

Outcome Measures

Primary Outcome Measures

Effect of treatment on the movement disorder will be measured by a myoclonus scale and a dystonia scale as well as by assessment of overall functional status. Response at various dosages will be compared to baseline for all patients. [Up to 12 weeks]

Secondary Outcome Measures

Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication. [Up to 16 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients should meet diagnostic criteria for M-D based on the following criteria:
myoclonus is the primary feature; focal or segmental dystonia of any severity may also be present
symptoms began by age 20
a familial pattern should be present
neurological history should not be suggestive of a different neurological condition
investigations such as imaging, EEG and evoked potential tests should be normal
Patients will be eligible for this study if they are symptomatic on their current treatment, cannot tolerate current therapies, or are treatment naïve patients who have been explained treatment alternatives.

Exclusion Criteria:

Patients adequately controlled without side effects on a current M-D treatment
Current treatment with a barbiturate such as phenobarbital or primidone
Pregnant patients or patients who may become pregnant during the study
Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders
Patients with seizure disorders
Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin
Patient with significant general medical or clinical laboratory abnormalities